These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31099044)

  • 1. LncRNA NOC2L-4.1 functions as a tumor oncogene in cervical cancer progression by regulating the miR-630/YAP1 pathway.
    Wang Q; Ding J; Nan G; Lyu Y; Ni G
    J Cell Biochem; 2019 Oct; 120(10):16913-16920. PubMed ID: 31099044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis.
    Yan H; Li H; Li P; Li X; Lin J; Zhu L; Silva MA; Wang X; Wang P; Zhang Z
    J Exp Clin Cancer Res; 2018 Sep; 37(1):237. PubMed ID: 30249278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA PICSAR knockdown inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-125b/YAP1 axis.
    Lu X; Gan Q; Gan C; Zheng Y; Cai B; Li X; Li D; Yin G
    Life Sci; 2021 Jun; 274():118303. PubMed ID: 32841663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA LINC00152 Increases the Aggressiveness of Human Retinoblastoma and Enhances Carboplatin and Adriamycin Resistance by Regulating MiR-613/Yes-Associated Protein 1 (YAP1) Axis.
    Wang Y; Xin D; Zhou L
    Med Sci Monit; 2020 Jun; 26():e920886. PubMed ID: 32541644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer.
    Yan H; Li H; Silva MA; Guan Y; Yang L; Zhu L; Zhang Z; Li G; Ren C
    J Exp Clin Cancer Res; 2019 Aug; 38(1):356. PubMed ID: 31412903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3K27 acetylation-induced lncRNA EIF3J-AS1 improved proliferation and impeded apoptosis of colorectal cancer through miR-3163/YAP1 axis.
    Liu D; Zhang H; Cong J; Cui M; Ma M; Zhang F; Sun H; Chen C
    J Cell Biochem; 2020 Feb; 121(2):1923-1933. PubMed ID: 31709617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA BBOX1-AS1 upregulates HOXC6 expression through miR-361-3p and HuR to drive cervical cancer progression.
    Xu J; Yang B; Wang L; Zhu Y; Zhu X; Xia Z; Zhao Z; Xu L
    Cell Prolif; 2020 Jul; 53(7):e12823. PubMed ID: 32515533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p.
    Wang H; Di X; Bi Y; Sun S; Wang T
    Bioengineered; 2021 Dec; 12(1):1791-1802. PubMed ID: 33975517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA kcna3 inhibits the progression of colorectal carcinoma through down-regulating YAP1 expression.
    Zhong X; Lü M; Wan J; Zhou T; Qin B
    Biomed Pharmacother; 2018 Nov; 107():382-389. PubMed ID: 30099342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The knockdown of SNHG3 inhibits the progression of laryngeal squamous cell carcinoma by miR-340-5p/YAP1 axis and Wnt/β-catenin pathway.
    Kang R; Yao DF; Xu GZ; Zhou YH
    Neoplasma; 2020 Sep; 67(5):1094-1105. PubMed ID: 32538668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA AL592284.1 facilitates proliferation and metastasis of cervical cancer cells via miR-30a-5p/Vimentin/EMT axis.
    Zhang J; Liu HL; Liu JB; Zhang Y; Liu J; Li YH
    Biochem Biophys Res Commun; 2021 Nov; 577():95-102. PubMed ID: 34509725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lncRNA LINC00675 regulates cell proliferation, migration, and invasion by affecting Wnt/β-catenin signaling in cervical cancer.
    Ma S; Deng X; Yang Y; Zhang Q; Zhou T; Liu Z
    Biomed Pharmacother; 2018 Dec; 108():1686-1693. PubMed ID: 30372871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DLG1-AS1/miR-497/YAP1 axis regulates papillary thyroid cancer progression.
    Huang Y; Zhang K; Li Y; Dai Y; Zhao H
    Aging (Albany NY); 2020 Nov; 12(22):23326-23336. PubMed ID: 33197895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA
    Guo Q; Zhang Q; Lu L; Xu Y
    Cell Cycle; 2020 May; 19(10):1222-1235. PubMed ID: 32264732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1.
    Li X; Li Y; Han Y; Dong B; Liu D; Che L; Liu Y; Wang Y
    Cancer Biother Radiopharm; 2020 Jun; 35(5):338-344. PubMed ID: 32379984
    [No Abstract]   [Full Text] [Related]  

  • 17. Long noncoding RNA SOX21-AS1 promotes cervical cancer progression by competitively sponging miR-7/VDAC1.
    Zhang X; Zhao X; Li Y; Zhou Y; Zhang Z
    J Cell Physiol; 2019 Aug; 234(10):17494-17504. PubMed ID: 30912129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma.
    Wu DM; Wang S; Wen X; Han XR; Wang YJ; Shen M; Fan SH; Zhang ZF; Shan Q; Li MQ; Hu B; Lu J; Chen GQ; Zheng YL
    Cell Death Dis; 2018 Sep; 9(10):947. PubMed ID: 30237435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway.
    Sun Y; Jiang T; Jia Y; Zou J; Wang X; Gu W
    Cell Cycle; 2019 Oct; 18(19):2509-2523. PubMed ID: 31397203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the long non-coding RNA UNC5B-AS1/miR-4455/RSPO4 axis reduces cervical cancer growth in vitro and in vivo.
    Fu J; Zhang Y; Wang M; Hu J; Fang Y
    J Gene Med; 2021 Dec; 23(12):e3382. PubMed ID: 34350661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.